Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2356 publications
Immune checkpoint inhibitor-induced nephrotic syndrome: a pharmacovigilance analysis of 404 FAERS cases and literature case series.
Journal: Renal failure
Published: October 14, 2025
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 13, 2025
PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive Bladder Cancer: Erratum.
Journal: The Journal of urology
Published: October 09, 2025
Adverse Events of Immune Checkpoint Inhibitors in Cancer Patients with Comorbid Diabetes: A Real-World Pharmacovigilance Analysis of the FDA Adverse Event Reporting System Database (2011-2025).
Journal: Cancer control : journal of the Moffitt Cancer Center
Published: September 19, 2025
Unresectable stage III non-small-cell lung cancer: state of the art and challenges.
Journal: Nature reviews. Clinical oncology
Published: September 15, 2025
Agranulocytosis Following Durvalumab Plus Tremelimumab Therapy for Hepatocellular Carcinoma: A Case Report.
Journal: Internal medicine (Tokyo, Japan)
Published: September 10, 2025
ASO Visual Abstract: Real-World Single-Center Experience with Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab in Borderline Resectable Cholangiocarcinoma.
Journal: Annals of surgical oncology
Published: September 08, 2025
Noninvasive ImmunoPET imaging of PD-L1 expression in non-small cell lung cancer and bladder cancer using [89Zr]Zr-DFO-Durvalumab.
Journal: Colloids and surfaces. A, Physicochemical and engineering aspects
Published: September 08, 2025
Update on the Treatment of Non-Small Cell Lung Carcinoma (NSCLC).
Journal: Journal of clinical medicine
Published: September 07, 2025
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer.
Journal: medRxiv : the preprint server for health sciences
Published: September 05, 2025
The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular Carcinoma.
Journal: Internal medicine (Tokyo, Japan)
Published: September 03, 2025
Immune Checkpoint Inhibitor-Induced Subacute Myocarditis.
Journal: Cureus
Published: September 02, 2025
Last Updated: 10/31/2025